What changed from existing technology?
This study tested a new drug called birelentinib for treating a type of lymph cancer that comes back or doesn't respond to other treatments. The drug showed some success in shrinking tumors and helping patients feel better.
Birelentinib is a first-in-class dual inhibitor targeting both LYN and BTK, which is different from existing treatments that typically target only one of these pathways.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
n relapsed/refractory diffuse large B-cell lymphoma: a phase 2 study (TAI-SHAN9). In this phase 2 TAI-SHAN9 study, we evaluated the safety and efficacy of bi
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
Birelentinib may be a potential treatment option for patients with relapsed/refractory diffuse large B-cell lymphoma, particularly those who have not responded to other therapies.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.